Antioxidant Action Of Vitamin E Significantly Reduces Heart Disease In Mice

September 29, 1998

In mice genetically manipulated to develop atherosclerosis, scientists at the University of Pennsylvania Medical Center have for the first time conclusively demonstrated that vitamin E confers potent protection from the disease. Atherosclerotic damage to cardiovascular tissues was limited by about 40 percent in at-risk mice receiving doses of the vitamin for only 16 weeks.

The researchers were also able to show that the benefit was due to the antioxidant action of vitamin E, not to other possible effects such as a reduction in blood cholesterol levels. This fact strongly suggests that free radicals do, in fact, play a central role in heart disease, a theory long proposed but never proven. A novel method recently developed by the same group for directly measuring oxidant stress in the body provided the data in support of the observations.

A report on the new findings appears in the October issue of Nature Medicine.

"This study offers powerful evidence for the efficacy of vitamin E as an antioxidant in atherosclerosis," says Garret A FitzGerald, MD, chairman of the department pharmacology and senior author on the report. "Significantly, it also shows that free-radical injury is functionally important in the development of cardiovascular disease."

The innovative measurement technique used in the study was developed in FitzGerald's laboratory in collaboration with Joshua Rokach, PhD, a chemist at the Florida Institute of Technology. It assesses the levels in blood or urine of certain biochemicals called isoprostanes. These isoprostanes are stable byproducts of free-radical catalyzed damage to lipids, or fatty molecules, found in tissues throughout the body, and they serve as quantitative markers for that damage.

The strain of mice used in the experiments has been genetically engineered to lack the apoE gene, resulting in extremely high levels of cholesterol and triglycerides in their blood. Atherosclerotic lesions develop in the cardiovasculature of these mice that are similar to those seen in humans with the disease.

Using the isoprostane assay, the investigators were able to determine not only the degree of oxidant stress at work in the mice but also the precise effects of the vitamin E given as an experimental intervention to counter the corrosive process. The results showed that lesions were reduced from 31.7 percent of the aortic arch surface area in the untreated mice to 19.3 percent in the mice receiving vitamin E for 16 weeks, an improvement of approximately 40 percent.

According to FitzGerald, the measure of lipid oxidation used in these experiments could form the basis for clinical trials to test effectively the use of antioxidants against a range of diseases in humans. In recently published studies, his laboratory has demonstrated that levels of the isoprostanes are also increased in human atherosclerosis.

He notes that trials to date of antioxidants have resulted in conflicted findings, perhaps because it could not be known whether the volunteers were under high oxidant stress to begin and, thus, able to benefit from the antioxidant vitamins and other compounds being tested. Also, because antioxidants like vitamins C and E have been shown in the test tube to act as prooxidants when used at high levels, the assay could be used to determine the doses of an antioxidant that would be beneficial rather than damaging.

"One's responsiveness to an antioxidant is a function of the degree to which the oxidation system is activated," FitzGerald says. "So, in clinical trials where there's no biochemical basis for either selecting a dose or identifying patients susceptible to respond, the results can be skewed and erroneous conclusions can be drawn from them."

He adds: "We need to know which individuals should take an antioxidant like vitamin E, because it's not entirely innocuous, and we need to know what dose would be beneficial for them -- as is the case with any drug."

The lead author on the study was Domenico Pratico, MD, an assistant professor of pharmacology, and Rajendra K. Tangirala, MD, was a coauthor. Daniel J. Rader, MD, an assistant professor of medicine, collaborated on the study. Funding was provided by the National Institutes of Health, the National Science Foundation, the American Heart Association, and the W.W. Smith Charitable Trust.

The University of Pennsylvania Medical Center's sponsored research and training ranks third in the United States based on grant support from the National Institutes of Health, the primary funder of biomedical research and training in the nation -- $175 million in federal fiscal year 1997. In addition, for the third consecutive year, the institution posted the highest annual growth in these areas -- 17.6 percent -- of the top ten U.S. academic medical centers. News releases from the University of Pennsylvania Medical Center are available to reporters by direct e-mail, fax, or U.S. mail, upon request. They are also posted electronically to the medical center's home page (http://www.med.upenn.edu), to EurekAlert! (http://www.eurekalert.org), an Internet resource sponsored by the American Association for the Advancement of Science, and to the electronic news services SciNews-MedNews and Quadnet.
-end-


University of Pennsylvania School of Medicine

Related Heart Disease Articles from Brightsurf:

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

With a heavy heart: How men and women develop heart disease differently
A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated.

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.

Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.

New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.

Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.

Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.

Read More: Heart Disease News and Heart Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.